A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib

被引：0

作者：

David Proudman

Dave Nellesen

Deepshekhar Gupta

Deyaa Adib

Jay Yang

Khalid Mamlouk

机构：

[1] Analysis Group,

[2] Inc.,undefined

[3] Epizyme,undefined

[4] Inc.,undefined

来源：

Advances in Therapy | 2022年 / 39卷

关键词：

Aliqopa; Anticancer agents; Copiktra; Relapsed/refractory follicular lymphoma; Tazverik; Ukoniq; Zydelig;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1678 / 1696

页数：18

共 64 条

[1]

Fowler NH(2021)Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma J Clin Oncol 39 1609-1618

[2]

Samaniego F(2013)EZH2 mutations are frequent and represent an early event in follicular lymphoma Blood 122 3165-3168

[3]

Jurczak W(2017)EZH2 alterations in follicular lymphoma: biological and clinical correlations Blood Cancer J 7 3078-3086

[4]

Bodor C(2014)EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations Clin Cancer Res 20 726-729

[5]

Grossmann V(2011)EZH2 Y641 mutations in follicular lymphoma Leukemia 25 21-29

[6]

Popov N(2008)Roles of the EZH2 histone methyltransferase in cancer epigenetics Mutat Res 647 677-692

[7]

Huet S(2013)EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation Cancer Cell 23 343-349

[8]

Xerri L(2011)The Polycomb complex PRC2 and its mark in life Nature 469 1008-1018

[9]

Tesson B(2014)PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma N Engl J Med 370 912-922

[10]

Guo S(2019)DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma J Clin Oncol 37 362-371